Table-1.
Treatments | aCSF (n=5) | 1 mM muscimol (n=4) | 10 mM muscimol (n=5) | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Cell types /regions studied | Single | Double | Total | Single | Double | Total | Single | Double | Total | |
HCRT neurons | PF | 137 ± 15 | 15 ± 05 | 152 ± 11 | 120 ± 19 | 27 ± 08 | 147 ± 15 | 72 ± 14 | 61 ± 12** | 134 ± 04 |
Medial | 48 ± 05 | 03 ± 01 | 50 ± 05 | 53 ± 09 | 06 ± 01 | 58 ± 09 | 30 ± 06 | 23 ± 06** | 52 ± 05 | |
Lateral | 53 ± 04 | 07 ± 03 | 60 ± 03 | 50 ± 07 | 10 ± 03 | 60 ± 05 | 30 ± 07 | 31 ± 07** | 61 ± 03 | |
Total | 238 ± 17 | 24 ± 09 | 262 ± 09 | 222 ± 31 | 43 ± 12 | 265 ± 24 | 132 ± 26 | 115 ± 25** | 247 ± 04 | |
MCH neurons | PF | 232 ± 26 | 02 ± 01 | 234 ± 26 | 267 ± 30 | 01 ± 01 | 268 ± 31 | 236 ± 15 | 01 ± 01 | 238 ± 15 |
Medial | 55 ± 07 | 01 ± 01 | 55 ± 07 | 54 ± 09 | 01 ± 01 | 55 ± 09 | 49 ± 06 | 01 ± 01 | 49 ± 06 | |
Lateral | 204 ± 29 | 02 ± 01 | 204 ± 28 | 213 ± 17 | 01 ± 01 | 214 ± 17 | 196 ± 14 | 02 ± 01 | 198 ± 14 | |
Total | 489 ± 49 | 05 ± 02 | 494 ± 48 | 534 ± 50 | 03 ± 01 | 537 ± 50 | 482 ± 21 | 04 ± 01 | 486 ± 22 | |
Single Fos+ | PF | 94 ± 23 | 94 ± 23 | 126 ± 16 | 126 ± 16 | 166 ± 16 | 166 ± 16* | |||
Medial | 61 ± 17 | 61 ± 17 | 98 ± 19 | 98 ± 19 | 171 ± 11 | 171 ± 11** | ||||
Lateral | 27 ± 08 | 27 ± 08 | 34 ± 09 | 34 ± 09 | 58 ± 09 | 58 ± 09 | ||||
Total | 181 ± 47 | 181 ± 47 | 258 ± 42 | 258 ± 42 | 395 ± 17 | 395 ± 17** | ||||
5-HT neurons | DRN | 376 ± 19 | 08 ± 02 | 383 ± 21 | 382 ± 10 | 11 ± 02 | 393 ± 09 | 363 ± 10 | 17 ± 03* | 380 ± 13 |
Single Fos+ | DRN | 96 ± 18 | 96 ± 18 | 123 ± 09 | 123 ± 09 | 139 ± 10 | 139 ± 10 |
as compared to aCSF; <0.05
<0.01 level of significance.
Counts (mean ± S.E.M.) and are based on average of three sections counted bilaterally per animal.